Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Share Price

News coverage about Anika Therapeutics (NASDAQ:ANIK) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.5690405048481 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of ANIK opened at $49.72 on Monday. The stock has a market cap of $730.58, a P/E ratio of 25.37, a P/E/G ratio of 3.17 and a beta of 1.73. Anika Therapeutics has a 52-week low of $42.17 and a 52-week high of $69.81.

How to Become a New Pot Stock Millionaire

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.03). The company had revenue of $29.39 million for the quarter, compared to analysts’ expectations of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the company posted $0.54 EPS. analysts expect that Anika Therapeutics will post 1.57 earnings per share for the current fiscal year.

A number of research analysts have recently commented on the company. Sidoti assumed coverage on Anika Therapeutics in a research report on Friday, January 26th. They set a “buy” rating on the stock. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 26th. First Analysis raised Anika Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $45.00 to $68.00 in a report on Wednesday, January 24th. Barrington Research cut Anika Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, February 23rd. Finally, Zacks Investment Research cut Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $62.50.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Share Price” was first published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply